** Shares in Galderma GALD.S rise 5.7% after the company posted Q1 results that beat expectations, driven by higher sales, especially in its Injectable Aesthetics division
** Sales in Injectable Aesthetics were up 9.9% y/y, which analysts at Jefferies and J.P. Morgan point to as 6% above consensus, driven primarily by Neuromodulators sales
** U.S. sales did not reach consensus expectations but this was offset by "pleasing double-digits" growth in international sales, Vontobel says
** The U.S. sales launch of atopic dermatitis and prurigo nodularis medication Nemluvio was stronger than expected, analysts say, with Jefferies seeing the trajectory as "promising when compared to Sanofi SASY.PA/Regeneron's REGN.O Dupixent and Eli Lilly's LLY.N Ebglyss"
** Up to the previous session's close, shares were down 19.9% YTD
(Reporting by Bernadette Hogg)
((bernadette.hogg@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。